Accueil   Diary - News   All news First sales of Flu Vaccines Produced on Valneva’s EB66® Cell-Line

First sales of Flu Vaccines Produced on Valneva’s EB66® Cell-Line

valvena photos pied de pageValneva to begin receiving royalties for an EB66®-based human vaccine in
2016


Valneva SE (“Valneva” or “the Company”), a leading pure play vaccine company, announces today that GlaxoSmithKline (GSK) in collaboration with one of its partners has for the first time supplied pre-pandemic influenza vaccines based on Valneva’s EB66® cell line.

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree